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aSaudi ArabiaBackground: Mitral regurgitation (MR) is a frequent finding in patients with aortic stenosis (AS). The objective of
this study is to assess the change in MR severity following transcatheter aortic valve implantation (TAVI).
Methods: MR changes were assessed by comparing transthoracic echocardiography before and after the
procedure.
Results: The prosthetic aortic valve was successfully implanted in 65 patients. The number of patients with pre-
procedure MR was reduced from 58 (85.3%) to 43 (63.2%) (p < 0.001). Vena contracta width was decreased from
0.47 ± 0.28 to 0.25 ± 0.21, (p = 0.043). About 59.4% (19/32) of those who had moderate to severe MR and 85.7% (12/
14) of those with severe MR experienced a significant improvement in MR after the procedure (p < 0.001). Improve-
ment in MR was independent of prosthetic valve type with 54.2% in CoreValve and 43.9% in Edwards SAPIEN,
p = 0.424; valve sizes were 25.8 ± 1.9 in those who improved vs. 25.0 ± 1.9 mm in those who did not improve,
p = 0.105; femoral approach was 51.2% and apical approach was 41.7%, p = 0.457; MR etiology was 48.1% in organic
and 48.6% in functional, p = 0.968; and operative risk was 50.0% in EuroScore >20 and 48.6% in EuroScore <20,
p = 0.356.
Conclusions: TAVI is associated with a significant improvement in MR, especially in severe types. The lack of
influence of MR improvement by the etiology of MR, the type of valve implanted, and the operative risk need to
be confirmed in a larger multi-center study.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Keywords: TAVI, Mitral regurgitation, Aortic stenosisBackground
Transcatheter aortic valve implantation (TAVI)has been recognized as an alternative
therapeutic option for patients with severe
symptomatic aortic stenosis (AS), and high surgi-
cal risk [1,2]. Thirty to forty percent of patients
with symptomatic AS are inoperable, and almosthalf of them fulfill the criteria for TAVI [3,4].
Compared to standard surgical aortic valve repair,
TAVI procedure is shown to have comparable
survival among patients with severe AS who are
considered suitable candidates for surgery [5],
and to significantly improve survival among
patients with severe AS who are not considered
Abbreviations
TAVI transcatheter aortic valve implantation
AS aortic stenosis
MR mitral regurgitation
AVR aortic valve replacement
LVEF left ventricular ejection fraction
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MR CHANGE AFTER TAVIsuitable candidates for surgery [6]. After 10 years
of experience, TAVI is now considered a standard
therapeutic option for AS patients with prohibi-
tive risk for standard surgical management [4,7].
Mitral regurgitation (MR) is a frequent finding
in patients with severe AS [8]. MR is shown to
increase mortality risk after surgical aortic valve
replacement (AVR) [9]. However, MR may
improve significantly following isolated surgical
AVR [10]. The change in MR severity after TAVI
procedure was examined in several studies with
generally positive findings [11–18]. Patients who
experienced MR improvement in these studies
ranged between 17% and 28% while those who
experienced MR worsening ranged between 11%
and 22% [11,12,14]. The exact predictors of such
improvement are not well understood [11,13].
Moreover, whether MR improvement is associ-
ated with better survival after TAVI procedure is
unclear. The objective of the current study is to
assess the change in MR severity following TAVI
as well as to identify patient and procedural
characteristics associated with MR improvement.Methods
Patient population
The study population consists of 65 consecutive
patients who underwent successful TAVI using
the CoreValve (Medtronic CoreValve, Minneapo-
lis, Minnesota) or Edwards SAPIEN (Edwards
Lifesciences, Inc, Irvine, CA) heart valves between
April 2009 and November 2011. Patients were
considered as TAVI candidates if they had
severe symptomatic native aortic stenosis (AS) and
were at high or prohibitive surgical risk. Severe AS
was defined as aortic valve area <1 cm2 or <0.6 cm2/
m2, amean aortic-valve gradient ofP40 mmHgor a
peak aortic-jet velocity of P4.0 m/s, measured by
echocardiography.High or prohibitive surgical risk
was considered when the patient was >80 years
with life expectancy of >12 months, patients with
>70 years with Logistic EuroScore >20 [19], or
concomitant comorbid conditions assessed and
agreed to by both an independent cardiologist
and a cardiovascular surgeon.
Procedures were carried out under conscious
sedation or general anesthesia via transfemoral
approach for CoreValve aortic valve and via trans-
femoral or transapical approaches for Edwards
SAPIEN heart-valve. Transfemoral was the
approach of choice where feasible. The selection
of the type and size of the valve was based on
the measurements of the aortic valve annulus
obtained by CT angiography, and transthoracicechocardiography. All patients gave informed
consent, and the study was approved by the Insti-
tutional Ethics Committee.Echocardiography
Transthoracic echocardiography was performed
before and after TAVI procedure. All echocardio-
grams were obtained with the patient in a stable
hemodynamic condition. In the apical three- or
five-chamber view, the peak and mean pressure
gradients across the aortic valve were measured.
The annulus diameter was measured at the level
of insertion of the leaflets in the longitudinal view.
Aortic valve area was calculated using the conti-
nuity equation approach [20]. Quantification of
the left ventricular ejection fraction (LVEF) was
performed using left ventricular end-diastolic
and end-systolic dimensions [21]. The color-flow
Doppler signal was used to assess the presence
and the grade of aortic regurgitation.MR assessment
There were two independent expert readers
and, in case of disparity, a third reader to assess
the degree of MR. MR was assessed by visual
inspection, calculating vena contracta, and by
using color-flow mapping of the regurgitant jet
[22]. The vena contracta (contracted zone of the
Doppler color flow image of the jet at its passage
through an incompetent mitral valve) was
measured from the long axis apical view. Mitral
regurgitation was graded according to the Euro-
pean Society of Cardiology guidelines and the
American Society of Echocardiography recom-
mendations [23,24]. Therefore, MR was assessed
by visual inspection and by using color-flow
mapping of the regurgitant jet. The maximum jet
area was measured by planimetry where it
reached its greatest percentage of Left Atrial area,
in the four-chamber apical view, with the use of
Curad offline analysis package. MR jet area was
then expressed as a percentage of the left atrium
area (MR percentage), and its severity was graded
as follows: none 65%, mild 5–20%, moderate
20–40%, and severe P40%. Organic MR etiology
was defined as the presence of moderate to severe
Table 1. Change in mitral regurgitation (MR) following
transcatheter aortic valve implantation (TAVI).
Pre-procedure Post-procedure p-value
MR degree
No MR 7 (10.8%) 21 (32.3%) <0.001*
Mild MR 26 (40.0%) 25 (38.5%)
Moderate MR 18 (27.7%) 16 (24.6%)
Severe MR 14 (21.5%) 3 (4.6%)
MR change
Improved 31 (47.7%)
Unchanged 33 (50.8%)
Worsen 1 (1.5%)
* McNemar–Bowker test.
Figure 1. Change in mitral regurgitation (MR) following transcat.
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lus and/or leaflets; while functional MR etiology
was defined as the presence of LV dysfunction
with the absence of morphological abnormalities
of the mitral apparatus [9,25].
Survival
Survival was defined at 30 days and overall (any
time) during the study. Survival was followed up
through to November 2011.
Statistical analysis
Data were presented as frequencies and
percentages for categorical variables and
mean ± standard deviations for continuous vari-
ables. The McNemar–Bowker test was used to
evaluate significant differences of categorical
variables (MR grade) before and after TAVI proce-
dure. Paired t-test or the Wilcoxon signed-rank
test, as appropriate, were used to analyze signifi-
cant differences of continuous variables before
and after TAVI procedure. Chi-square or Fisher’s
tests, as appropriate, were used to evaluate signif-
icant differences of categorical variables between
those with and without MR improvement.
Unpaired Student’s t-test or the Mann–Whitney
test as appropriate, were used to determine
significant differences of continuous variables
between the two study groups. Mortality-free
survival was examined using the Kaplan–Meier
estimator. All p-values were two-tailed. P-value
<0.05 was considered significant. SPSS software
(release 17.0, SPSS Inc., Chicago, U.S.) was used
for all statistical analyses.Results
Sixty-five consecutive patients underwent suc-
cessful TAVI procedure between April 2009 and
November 2011. The number of patients with
MR was reduced after TAVI from 58 (85.3%) to
43 (63.2%), p < 0.001. Twelve of 14 patients
(85.7%), seven of 18 patients (38.9%), and 12 of 26
patients (46.2%) with severe, moderate and mild
MR respectively had improved MR (p < 0.001).
This represented 47.7% of those who had any
degree of MR and 59.4% of those who had
moderate to severe MR. Only one patient (1.5%)
experienced worsening of the MR grade (from
moderate to severe). See Table 1 and Fig. 1. Vena
contracta width was decreased from 0.47 ± 0.28 to
0.25 ± 0.21, p = 0.043.
Patients’ demographic and clinical characteris-
tics by post-procedure MR improvement are
summarized in Table 2. About 42% of both groupshad organic MR, and the average EuroScore (used
to assess surgical risk in the studied cohort) was
23.1 ± 16.4. MR improvement was not associated
with MR etiology (48.1% in organic vs. 48.6%
in functional, p = 0.968) nor operative risk (50.0%
in EuroScore >20 vs. 48.6% in EuroScore <20,
p = 0.356). Review of medical history revealed that
patients with improved MR were less likely to
have hypertension (61% vs. 84%, p = 0.039) than
those without improved MR. There was a trend
of lower prevalence of diabetes (58% vs. 78%,
p = 0.087); and myocardial infarction (13% vs.
31%, p = 0.080), compared to those without MR
improvement. No differences were noted between
the two patient groups in their medical histories of
chronic obstructive pulmonary disease, coronary
artery disease, coronary artery bypass graft,
stroke, carotid disease, atrial fibrillation, or
peripheral vascular disease.
Prosthetic valve characteristics and echocardio-
graphicfindingsbypost-procedureMR improvement
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Table 2. Characteristics of patients undergoing TAVI by post-procedure MR improvement.
Improved (N = 31) Not-improved (N = 34) p-value
Age (years) 78.7 ± 10.2 77.6 ± 10.1 0.648
Gender 0.180
Male 17 (54.8%) 13 (38.2%)
Female 14 (45.2%) 21 (61.8%)
Body mass index 28.5 ± 7.2 31.1 ± 5.6 0.109
Normal 8 (25.8%) 7 (20.6%) 0.229
Overweight 13 (41.9%) 9 (26.5%)
Obese 10 (32.3%) 18 (52.9%)
Blood pressure (mmHg)
Systolic 136.5 ± 25.2 135.8 ± 25.9 0.908
Diastolic 66.3 ± 11.7 67.3 ± 11.8 0.751
Heart rate 74.8 ± 12.3 73.0 ± 14.7 0.609
EuroScore for operative risk 26.3 ± 19.3 19.9 ± 12.5 0.126
Low risk (620) 17 (48.6%) 18 (51.4%) 0.356
High risk (>20) 14 (50.0%) 14 (50.0%)
MR cause 0.968
Functional 18 (48.6%) 19 (51.4%)
Organic 13 (48.1%) 14 (51.9%)
Medical history
Hypertension 19 (61.3%) 27 (84.4%) 0.039
Diabetes 18 (58.1%) 25 (78.1%) 0.087
Chornic obstructive pulmonary disease 7 (22.6%) 10 (31.2%) 0.438
Coronary artery disease 14 (45.2%) 20 (60.6%) 0.216
Myocardial infarction 4 (12.9%) 10 (31.2%) 0.080
CABG 4 (12.9%) 7 (20.6%) 0.409
Stroke 3 (9.7%) 5 (15.6%) 0.708
Carotid disease 8 (25.8%) 9 (27.3%) 0.894
Atrial fibrillation 8 (26.7%) 4 (13.3%) 0.197
Peripheral vascular disease 17 (58.6%) 19 (63.3%) 0.711
Percutaneous coronary intervention 11 (35.5%) 10 (30.3%) 0.659
Hemoglobin (g/dl) 12.1 ± 1.3 12.2 ± 1.7 0.815
Anemia 13 (44.8%) 11 (37.9%) 0.594
Platelets count (1000/ll) 266.0 ± 65.5 252.5 ± 76.5 0.480
Serum creatinine (mg/dl) 1.09 ± 0.78 1.05 ± 0.52 0.882
Hospital stay (days) 20.9 ± 18.6 14.9 ± 9.0 0.284
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MR CHANGE AFTER TAVIare summarized in Table 3. Echocardiographic find-
ings were evaluated within an average of
4.4 ± 3.8 months after TAVI with 84% done within
the first six months. The improvement in MR was
54.2% in CoreValve compared to 43.9% in Edwards
(p = 0.424), and was 51.2% in femoral approach com-
pared to 41.7% in transapical approach (p = 0.457).
Both the peak and mean pressure gradients across
the aortic valve were similarly improved among
patients with and without MR improvement. The
reduction in pulmonary artery pressure after the
procedure was seenmore commonly among patients
withMRimprovement (8.3 ± 13.8vs.0.7 ± 14.0 mmHg,
p = 0.049). LV ejection fraction did not change
among patients with or without MR improvement
(1.5 ± 7.1 vs. 0.8 ± 7.2 mmHg, p = 0.214).
There were no significant differences in post-
procedural complications between the two MR
improvement groups (Table 4). The incidence of
bleeding requiring blood transfusion, completeheart block requiring pacemaker implantation,
vascular injury, myocardial infarction, cerebrovas-
cular accident, acute renal failure, pericardial
effusion, sepsis, and wound infection were
similar in both groups. The 30-day mortality
period was not statistically different between the
two MR improvement groups, and the cause of
death was cardiac (60.0%) rather than non-cardiac
(40.0%).
Thirty-day survival was 94.1% and overall
survival was 88.2% during an average 12.5 ±
9.9 months of follow up. The Kaplan–Meier mor-
tality-free survival for the entire cohort and by
MR improvement groups is shown in Fig. 2.
There was no significant difference in survival
by MR improvement groups (p-value for Log
Rank test was 0.507). Likewise, survival was not
significantly different in relation to the EuroScore
operative risk group, type of prosthesis, or
procedural approach (p-values for Log Rank test
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Table 3. Prosthetic valve characteristics and echocardiographic findings among patients undergoing TAVI by post-procedure MR
improvement.
Improved (N = 31) Not-improved (N = 34) p-value
Valve type 0.424
Edwards SAPIEN 18 (43.9%) 23 (56.1%)
CoreValve 13 (54.2%) 11 (45.8%)
Valve approach 0.457
Femoral 21 (51.2%) 20 (48.8%)
Transapical 10 (41.7%) 14 (58.3%)
Prosthesis valve size (mm) 25.8 ± 1.9 25.0 ± 1.9 0.105
Aortic valve area (cm2) 0.59 ± 0.14 0.61 ± 0.14 0.493
Aortic annulus diameter (mm) 22.2 ± 1.8 21.5 ± 1.9 0.124
Pre-mean AV gradient (mm Hg) 52.2 ± 13.6 47.1 ± 11.9 0.112
Post-mean AV gradient (mm Hg) 11.4 ± 6.6 10.5 ± 4.7 0.529
Amount of mean AV change 40.8 ± 15.1 36.6 ± 11.8 0.222
p-value for change <0.001 <0.001
Pre-peak AV gradient (mm Hg) 91.6 ± 22.9 83.2 ± 20.7 0.123
Post-peak AV gradient (mm Hg) 20.0 ± 9.1 21.2 ± 8.9 0.611
Amount of peak AV change 71.6 ± 23.8 61.5 ± 20.3 0.071
p-value for change <0.001 <0.001
Pre-LV ejection fraction (%) 51.1 ± 11.8 50.0 ± 13.0 0.716
Post-LV ejection fraction (%) 52.5 ± 11.3 48.8 ± 13.2 0.235
Amount of LV ejection fraction change 1.5 ± 7.1 0.8 ± 7.2 0.214
p-value for change 0.256 0.544
Pre-pulmonary artery pressure (mmHg) 44.9 ± 14.5 41.6 ± 16.9 0.419
Post-pulmonary artery pressure (mmHg) 37.0 ± 13.2 41.0 ± 18.8 0.372
Amount of PAP change 8.3 ± 13.8 0.7 ± 14.0 0.049
p-value for change 0.005 0.793
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not shown).Discussion
We report a significant improvement in MR
after TAVI procedure. The improvement was
more evident in those with significant MR: 85.7%
of those who had severe MR, and 59.4% of those
who had moderate to severe MR. MR improve-
ment was observed in a number of studies
following the implantation of balloon expandable
Edwards valves [12,13,15–18]. In a multicenter
registry of 1,007 patients undergoing TAVI using
CoreValve, MR improvement was observed in
47% and 35% of patients with severe andTable 4. Post-procedure complications among patients undergoing
Improved
(N = 31)
Blood transfusion 9 (30.0%)
CHB requiring pacemaker 8 (26.7%)
Vascular 3 (10.0%)
Cerebrovascular accident 2 (6.5%)
Pericardial effusion 4 (13.8%)
Acute renal failure 1 (3.3%)
Sepsis 3 (9.7%)
Wound infection 1 (3.3%)
30-days mortality 0 (0.0%)moderate MR, respectively [16]. In two Canadian
centers, MR was improved in 55% of patients with
moderate or severe MR one year after TAVI using
different types of valves [18]. Durst et al. [13]
showed improvement in MR (evaluated by expert
readers and by the vena contracta in 35 patients)
over time after TAVI. Those who had moderate
to severe MR at baseline (53%) decreased to 38%
after three months and 19% after six months.
Additionally, Hekimian et al. [12] showed signifi-
cant improvement in MR grade (assessed using
integration of color Doppler jet area, vena contrac-
ta, and proximal isovelocity surface area) in 28% of
the patients at seven days (N = 99 patients), with
no further improvement observed at one month
(N = 60 patients). Similarly, Webb et al. [15]TAVI by post-procedure MR improvement.
Not-improved p-value
(N = 34)
11 (33.3%) 0.777
6 (18.2%) 0.418
5 (15.6%) 0.709
2 (5.9%) 1.000
3 (9.1%) 0.696
4 (12.5%) 0.355
0 (0.0%) 0.108
4 (12.1%) 0.357
2 (5.9%) 0.493
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Figure 2. Kaplan–Meier for mortality-free survival for the whole
cohort (A), by MR improvement group (B). Significant survival
differences were tested by Log Rank test.
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MR CHANGE AFTER TAVIreported a significant improvement in MR at dis-
charge with mild insignificant improvement
thereafter. The proportion of patients who had
moderate to severe MR at baseline (N = 24, 53%)
declined to 33%, 31%, 25% and 24% at discharge,
and at one, six, and 12 months, respectively.
A couple of studies failed to show any signifi-
cant MR improvement following the implantation
of CoreValve prosthesis [11,14]. Tzikas et al. [11]
reported no overall change in the degree of MR
evaluated in 74 patients using color-flow Doppler
at discharge and at the first outpatient visit after
TAVI. There were more patients with worsened
MR (22%) than with improved MR (17%). This
may be partially explained by the fact that our
population had more cases of moderate to severe
MR than the Tzikas study (49% vs. 19%). Those
who had moderate to severe MR in both studieshad the highest improvement frequency (59% in
our study compared to 60% in the Tzikas study).
Those who had mild MR had higher improvement
in our study compared to the Tzikas study (46%
vs. 8%). It is to be noted that our study had more
functional MR than organic MR patients (58% vs.
42%) compared to the Tzikas study (50% vs.
50%). Similarly, Gotzmann et al. [14] reported no
overall change in the degree of MR evaluated in
39 patients at 30 days and at six months after
TAVI. At six months, 10 patients (26%) had
improved MR while eight patients (21%) had
worsened MR. The lack of MR improvement in
the Gotzmann study is difficult to explain due to
both studies having the same proportion of severe
to moderate MR (49% each), and the lack of differ-
entiation between functional and organic causes
of MR in the Gotzmann study.
Theoretically, correcting AS abruptly reduces
LV systolic pressure, which results in a lower
transmitral systolic pressure gradient, which in
turn reduces the driving force of MR. Although
both the peak and mean pressure gradients across
the aortic valve in the current study were similarly
reduced among patients with and without
improved MR, there was a trend towards
improvement of the peak pressure gradient
among those with improved MR (p = 0.071). Early
improvement in MR after TAVI may be due to
an initial and rapid transvalvular pressure reduc-
tion, because the afterload is reduced immedi-
ately. Without stenosis, there is less pressure
gradient between the left ventricle and left atrium,
leading to reduced MR in the short term; whereas
persistent MR reduction may be secondary to
changes in the LV and mitral valve geometry
and in positive remodeling that occurs over time
[13,18].
MR improvement in the current study was not
influenced by MR etiology. A number of reports
show MR improvement after TAVI is more often
observed in functional MR [13,16,18], while others
could detect the influence of etiology [11,12,17].
Survival following TAVI in the current study was
high and comparable to previous studies [4,26].
Thirty-day survival in the current study was
94.1% while overall survival during an average of
12.5 months of follow-up was 88.2%. In a
meta-analysis of 12 TAVI studies, average 30-day
survival was 88.6% (77.0–94.7%), while one year
survival was 75.9% (64.1–87%) [26]. The observed
lack of association between MR improvement
and better survival has been reported and was
attributed to the negative effects of other comor-
bidities [16].
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Saudi Arabia and the region, had a relatively high
proportion (49%) of patients with moderate to
severe MR (potential candidates of MR improve-
ment) for its evaluation of the association between
valve type (CoreValve or Edwards SAPIEN) and
MR improvement. Nevertheless, we acknowledge
a number of limitations: the retrospective nature
of the study design, the relatively small number
of patients included, and the single center experi-
ence with no external independent adjudication.
The semi quantitative assessment of MR degree
and inconsistent timing of echocardiography
may subject our data to potential bias. Finally, lack
of longer-term follow up with more data on LV
changes in volumes and pressures is a further
limitation.Conclusion
We report a significant improvement in MR
after TAVI procedure, especially among those
with severe MR. The lack of influence on MR
improvement by MR etiology, the type of valve
implanted and operative risks need to be con-
firmed in a larger multi-center study. Such a study
should report prospective detailed echocardio-
graphic evaluation of the mitral valve before and
after TAVI to better predict patient and proce-
dural characteristics associated with immediate
and long term MR improvement.
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